Table 2.

Outcomes among of COVID-19 positive inpatients treated with baricitini /remdesivir/dexamethasone. Percentages may not total 100 because of rounding

	All patients (n = 45)
Primary outcomes:
Mortality over first 7 days following admission – no. (%)	2	(4.4)
Mortality over entire hospitalization – no. (%)	6	(13.3)
Secondary outcomes:
Diagnosis of hemodynamic shock during hospitalization – no. (%)	4	(8.9)
Thrombosis during hospitalization – no. (%)	-
Need for vasopressor support during hospitalization – no. (%)	4	(8.9)
Average duration of vasopressor support during hospitalization – days	1.5
New oxygen requirement during hospitalization – no. (%)	45	(100.0)
Average duration of new oxygen requirement (days)	7.9
Need for non-invasive ventilation – no. (%)	19	(42.2)
Average duration of non-invasive ventilation (days)	5.1
Need for mechanical ventilation during hospitalization – no. (%)	4	(8.9)
Average duration of mechanical ventilation during hospitalization (days)	3.75
Duration of hospitalization (days)	11
Estimated duration of illness (days)	15
Discharge status:
Home or self-care – no. (%)	26	(57.8)
Home with home health services – no. (%)	5	(11.1)
Subacute rehab – no. (%)	4	(8.9)
Skilled nursing facility – no. (%)	2	(4.4)
Transfer to another facility – no. (%)	2	(4.4)
Deceased – no. (%)	6	(13.3)